Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Change in Account Payables (2016 - 2025)

Rein Therapeutics filings provide 10 years of Change in Account Payables readings, the most recent being -$147000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 12.5% year-over-year to -$147000.0, compared with a TTM value of $3.1 million through Dec 2025, up 1198.57%, and an annual FY2025 reading of $3.1 million, up 1198.57% over the prior year.
  • Change in Account Payables hit -$147000.0 in Q4 2025 for Rein Therapeutics, up from -$1.9 million in the prior quarter.
  • The five-year high for Change in Account Payables was $4.9 million in Q2 2025, with the low at -$3.7 million in Q4 2023.
  • Median Change in Account Payables over the past 5 years was -$64000.0 (2021), compared with a mean of -$103600.0.
  • The sharpest move saw Change in Account Payables skyrocketed 573.96% in 2021, then plummeted 4289.47% in 2022.
  • Year by year, Change in Account Payables stood at $178000.0 in 2021, then soared by 335.39% to $775000.0 in 2022, then tumbled by 583.35% to -$3.7 million in 2023, then surged by 95.52% to -$168000.0 in 2024, then increased by 12.5% to -$147000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$147000.0, -$1.9 million, and $4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.